The influence of green tea extract on nintedanib's bioavailability in patients with pulmonary fibrosis.
Veerman GDM, van der Werff SC, Koolen SLW, Miedema JR, Oomen-de Hoop E, van der Mark SC, Chandoesing PP, de Bruijn P, Wijsenbeek MS, Mathijssen RHJ.
Veerman GDM, et al.
Biomed Pharmacother. 2022 Jul;151:113101. doi: 10.1016/j.biopha.2022.113101. Epub 2022 May 17.
Biomed Pharmacother. 2022.
PMID: 35594703
Free article.
Clinical Trial.
Nintedanib is an oral small-molecule kinase inhibitor and first-line treatment for idiopathic pulmonary fibrosis. Nintedanib is a substrate of the drug efflux transporter ABCB1. Green tea flavonoids --especially epigallocatechin gallate (EGCG)-- are potent ABCB1 modulators …
Nintedanib is an oral small-molecule kinase inhibitor and first-line treatment for idiopathic pulmonary fibrosis. Nintedanib is a substrate …